Head-to-head · Cost-Efficiency Index
Metaboost Rx vs NuBloom
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Metaboost Rx
Shoppers who don't mind entering an eligibility funnel to get a firm, itemized quote.
Visit Metaboost RxNuBloom
Cost-first shoppers who want a physician-founded, whole-person GLP-1 program for women, in the 49 states it publishes as covered.
Visit NuBloomThe verdict
Metaboost Rx and NuBloom tie on the Cost-Efficiency Index at 54/100, so neither wins outright on the numbers. For most shoppers we'd start with Metaboost Rx (ranked #359, a hair above #361) — Shoppers who don't mind entering an eligibility funnel to get a firm, itemized quote. But NuBloom is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Metaboost Rx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Metaboost Rx | NuBloom |
|---|---|---|
| Cost-Efficiency Index | 54/100 | 54/100 |
| Semaglutide / mo | $249/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide / mo | $299/mo (starting dose, compounded) | $249/mo (microdose tier, compounded) |
| Semaglutide / yr (modeled) | $2,988 | — |
| Tirzepatide / yr (modeled) | $3,588 | $2,988 |
| Coverage | Coverage not published | 49 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #359 | #361 |
Metaboost Rx
54/100Where the value is
- Publishes at least headline starting prices on the homepage, unlike some peers that hide all numbers
- '$0 if not approved' guarantee reduces risk of a wasted consultation fee
- Offers a microdose GLP-1 tier alongside standard semaglutide/tirzepatide
The tradeoffs
- Homepage price and product-page pricing don't match up -- dose tiers and confirmed rates are never shown together
- No named medical director or compounding pharmacy partner disclosed
NuBloom
54/100Where the value is
- Transparent, openly published starting pricing: semaglutide $149/mo, tirzepatide $279/mo, with a cheaper $249/mo microdose tirzepatide option
- Founded and medically led by a named, identifiable physician (Dr. Marianne Pinkston Mueller)
- Full state-coverage list published and independently countable: 49 states, all except Mississippi
The tradeoffs
- Compounding pharmacy partner is never named anywhere on the site — only 'a state-licensed sterile compounding pharmacy partner'
- NuBloom's own independent LegitScript status isn't distinctly confirmed; the certification language attaches to its telehealth-platform partner, Telegra
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.